Literature DB >> 27118602

Immunomodulatory effects of bone marrow versus adipose tissue-derived mesenchymal stromal cells on NK cells: implications in the transplantation setting.

Belén Blanco1, María Del Carmen Herrero-Sánchez1, Concepción Rodríguez-Serrano1, María Lourdes García-Martínez2, Juan F Blanco3, Sandra Muntión1, Mariano García-Arranz4, Fermín Sánchez-Guijo1, Consuelo Del Cañizo1.   

Abstract

INTRODUCTION: The ability of mesenchymal stromal cells (MSC) to suppress T-cell function has prompted their therapeutic use for graft-versus-host disease (GVHD) control. However, as MSC also modulate the activity of NK cells, which play an important role in graft-versus-leukemia (GVL) reaction, their administration could hamper this beneficial effect of allogeneic hematopoietic stem cell transplantation. MSC can be expanded from several sources, especially bone marrow and fat, but it is not well established if the cell source makes a difference in their immunoregulatory capacity.
OBJECTIVE: The aim of this study was to compare the immunomodulatory effect of MSC derived from bone marrow (BM-CSM) or adipose tissue (AT-MSC) on NK cells, to determine whether the use of MSC from one or the other origin could be more favorable to preserve NK cell activity and, therefore, GVL.
METHODS: Human NK cells were stimulated with IL-15 in the presence of BM-MSC or AT-MSC. The effect of both MSC populations on NK cell proliferation, cell cycle progression, and CD56 expression was analyzed by flow cytometry. Cytokine secretion was measured by ELISA, and cytotoxic activity was assessed by calcein release assays.
RESULTS: Although both BM-MSC and AT-MSC induced a similar inhibition of NK cell proliferation, only BM-MSC decreased significantly NK cell cytotoxic activity and showed a trend for a higher reduction of IFN-γ secretion.
CONCLUSION: These results suggest that, in the context of GVHD inhibition, the use of AT-MSC rather than BM-MSC could further preserve NK cell activity and, thus, favor GVL.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  NK cells; adipose tissue; bone marrow; graft-versus-leukemia; mesenchymal stromal cells

Mesh:

Substances:

Year:  2016        PMID: 27118602     DOI: 10.1111/ejh.12765

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  13 in total

1.  Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  Mol Cell Biochem       Date:  2018-01-30       Impact factor: 3.396

2.  Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  J Cell Commun Signal       Date:  2018-01-19       Impact factor: 5.782

3.  Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells.

Authors:  Ya Gao; Weiru Li; Xiaoyin Bu; Ying Xu; Shengchun Cai; Jinman Zhong; Meixue Du; Haitao Sun; Liping Huang; Yongjian He; Xiumei Hu; Qifa Liu; Hua Jin; Qian Wang; Baohong Ping
Journal:  J Inflamm Res       Date:  2021-08-16

Review 4.  Mesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering.

Authors:  Ross E B Fitzsimmons; Matthew S Mazurek; Agnes Soos; Craig A Simmons
Journal:  Stem Cells Int       Date:  2018-08-19       Impact factor: 5.443

5.  Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up.

Authors:  Juan F Blanco; Eva M Villarón; David Pescador; Carmen da Casa; Victoria Gómez; Alba M Redondo; Olga López-Villar; Miriam López-Parra; Sandra Muntión; Fermín Sánchez-Guijo
Journal:  Stem Cell Res Ther       Date:  2019-02-22       Impact factor: 6.832

Review 6.  The involving progress of MSCs based therapy in atherosclerosis.

Authors:  Ying Lin; Wei Zhu; Xiaomin Chen
Journal:  Stem Cell Res Ther       Date:  2020-06-05       Impact factor: 6.832

Review 7.  Mechanisms behind the Immunoregulatory Dialogue between Mesenchymal Stem Cells and Th17 Cells.

Authors:  Claudia Terraza-Aguirre; Mauricio Campos-Mora; Roberto Elizondo-Vega; Rafael A Contreras-López; Patricia Luz-Crawford; Christian Jorgensen; Farida Djouad
Journal:  Cells       Date:  2020-07-10       Impact factor: 6.600

8.  Inferior In Vivo Osteogenesis and Superior Angiogenesis of Human Adipose‐Derived Stem Cells Compared with Bone Marrow‐Derived Stem Cells Cultured in Xeno‐Free Conditions.

Authors:  Meadhbh A Brennan; Audrey Renaud; Fabien Guilloton; Miryam Mebarki; Valerie Trichet; Luc Sensebé; Frederic Deschaseaux; Nathalie Chevallier; Pierre Layrolle
Journal:  Stem Cells Transl Med       Date:  2017-10-19       Impact factor: 6.940

Review 9.  Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic Strategies.

Authors:  Yi-Heng Lin; Ya-Hsin Chen; Heng-Yu Chang; Heng-Kien Au; Chii-Ruey Tzeng; Yen-Hua Huang
Journal:  Int J Mol Sci       Date:  2018-08-13       Impact factor: 5.923

Review 10.  Current Status and Future Prospects of Genome-Scale Metabolic Modeling to Optimize the Use of Mesenchymal Stem Cells in Regenerative Medicine.

Authors:  Þóra Sigmarsdóttir; Sarah McGarrity; Óttar Rolfsson; James T Yurkovich; Ólafur E Sigurjónsson
Journal:  Front Bioeng Biotechnol       Date:  2020-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.